Exhibit 99.1
Results of 2024 Annual General Meeting
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 22 November 2024: In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions passed by the shareholders of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) at its Annual General Meeting held on 22 November 2024.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorised by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts: Australia
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S.
Remy Bernarda remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of section 27A of the identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward- looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company’s intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Disclosure of Proxy Votes
Alterity Therapeutics Limited
Annual General Meeting
Friday, 22 November 2024 |  |
| GPO Box 5193, Sydney, NSW 2001 |
| P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) |
| F +61 (0)2 8583 3040 E hello@automic.com.au |
| | ABN 27 152 260 814 |
In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.
| | | | Proxy Votes | Poll Results
(if applicable) | Results |
| Resolution | Decided by
Show of
Hands (S) or
Poll (P) | Total Number of
Proxy Votes
exercisable by
proxies validly
appointed | FOR | AGAINST | ABSTAIN | PROXY’S
DISCRETION | FOR | AGAINST | ABSTAIN | OUTCOME |
| 1 Non-binding resolution to adopt Remuneration Report | P | 360,278,902 | 247,282,902
68.64% | 87,766,213
24.36% | 27,512,053 | 25,229,787
7.00% | 272,623,588
75.65% | 87,766,213
24.35% | 27,512,053 | - |
| 2 Re-Election of Director – Mr Geoffrey Kempler | P | 393,912,798 | 326,330,105
82.84% | 42,974,739
10.91% | 2,862,414 | 24,607,954
6.25% | 376,435,438
89.75% | 42,974,739
10.25% | 2,862,414 | Carried |
| 3 Ratification of prior issue of shares (Placement July 2024) | P | 292,690,098 | 184,971,185
63.20% | 82,614,126
28.23% | 1,286,814 | 25,104,787
8.58% | 253,554,351
75.42% | 82,614,126
24.58% | 1,286,814 | Carried |
| 4 Approval for issue of options – Mr Geoffrey Kempler | P | 336,743,973 | 251,964,801
74.82% | 63,859,918
18.96% | 57,757,839 | 20,919,254
6.21% | 298,381,434
82.37% | 63,859,918
17.63% | 57,757,839 | Carried |
| 5 Approval for issue of options – Mr Lawrence Gozlan | P | 337,583,973 | 251,873,001
74.61% | 64,288,385
19.04% | 57,194,439 | 21,422,587
6.35% | 316,773,967
83.13% | 64,288,385
16.87% | 57,194,439 | Carried |
| 6 Approval for issue of options – Mr Peter Marks | P | 337,356,373 | 251,667,001
74.60% | 64,266,785
19.05% | 57,953,639 | 21,422,587
6.35% | 309,381,999
82.80% | 64,266,785
17.20% | 57,953,639 | Carried |
| 7 Approval for issue of options – Mr Brian Meltzer | P | 330,247,116 | 244,620,144
74.07% | 64,204,385
19.44% | 57,941,639 | 21,422,587
6.49% | 309,521,110
82.82% | 64,204,385
17.18% | 57,941,639 | Carried |
| 8 Approval of 10% Placement Issue | P | 391,033,484 | 266,912,465
68.26% | 99,500,946
25.45% | 5,255,128 | 24,620,073
6.30% | 335,010,917
77.10% | 99,500,946
22.90% | 5,255,128 | Carried |
